O'Melveny & Myers, Tian Yuan Law Firm and William Ji & Co. have represented China’s Simcere Pharmaceutical Group on its HK$3.57 billion ($460.6 million) Hong Kong IPO, with Herbert Smith Freehills and Jingtian & Gongcheng advising the joint sponsors.
The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which is on track to have its second-busiest year for equity capital markets ever in 2020. Recent such issuers include JHBP (CY) Holdings and Everest Medicines.
Simcere Pharmaceutical supplies branded generic pharmaceuticals to the Chinese market. It has increased investment in R&D in recent years, and has three R&D centres in Nanjing, Shanghai and Boston.
Partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie led the Herbert Smith Freehills team.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.